GeneBioTech (Korea) Alpha and Beta Analysis

086060 Stock  KRW 3,415  65.00  1.94%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as GeneBioTech Co. It also helps investors analyze the systematic and unsystematic risks associated with investing in GeneBioTech over a specified time horizon. Remember, high GeneBioTech's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to GeneBioTech's market risk premium analysis include:
Beta
0.074
Alpha
(0.01)
Risk
1.73
Sharpe Ratio
(0.01)
Expected Return
(0.01)
Please note that although GeneBioTech alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, GeneBioTech did 0.01  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of GeneBioTech Co stock's relative risk over its benchmark. GeneBioTech has a beta of 0.07  . As returns on the market increase, GeneBioTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding GeneBioTech is expected to be smaller as well. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out GeneBioTech Backtesting, GeneBioTech Valuation, GeneBioTech Correlation, GeneBioTech Hype Analysis, GeneBioTech Volatility, GeneBioTech History and analyze GeneBioTech Performance.

GeneBioTech Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. GeneBioTech market risk premium is the additional return an investor will receive from holding GeneBioTech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GeneBioTech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate GeneBioTech's performance over market.
α-0.01   β0.07

GeneBioTech expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of GeneBioTech's Buy-and-hold return. Our buy-and-hold chart shows how GeneBioTech performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

GeneBioTech Market Price Analysis

Market price analysis indicators help investors to evaluate how GeneBioTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading GeneBioTech shares will generate the highest return on investment. By understating and applying GeneBioTech stock market price indicators, traders can identify GeneBioTech position entry and exit signals to maximize returns.

GeneBioTech Return and Market Media

The median price of GeneBioTech for the period between Thu, Sep 19, 2024 and Wed, Dec 18, 2024 is 3445.0 with a coefficient of variation of 3.06. The daily time series for the period is distributed with a sample standard deviation of 104.94, arithmetic mean of 3429.17, and mean deviation of 80.18. The Stock did not receive any noticable media coverage during the period.
 Price Growth (%)  
       Timeline  

About GeneBioTech Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including GeneBioTech or other stocks. Alpha measures the amount that position in GeneBioTech has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GeneBioTech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GeneBioTech's short interest history, or implied volatility extrapolated from GeneBioTech options trading.

Build Portfolio with GeneBioTech

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Information on Investing in GeneBioTech Stock

GeneBioTech financial ratios help investors to determine whether GeneBioTech Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GeneBioTech with respect to the benefits of owning GeneBioTech security.